Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES RELIEF versus DRIXORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S ZYRTEC HIVES RELIEF versus DRIXORAL.
CHILDREN'S ZYRTEC HIVES RELIEF vs DRIXORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. It also inhibits eosinophil chemotaxis and mast cell mediator release.
Drixoral is a combination product containing dexbrompheniramine maleate, a first-generation antihistamine that competitively antagonizes histamine at H1 receptor sites, and pseudoephedrine sulfate, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and reducing nasal congestion.
For adults, the recommended dose of cetirizine (active ingredient in Children's Zyrtec Hives Relief) is 10 mg orally once daily. Route: oral. Frequency: once daily.
One pseudoephedrine 60 mg and dexbrompheniramine 2 mg tablet orally every 12 hours; maximum 2 tablets per 24 hours.
None Documented
None Documented
Terminal elimination half-life is 8-11 hours in healthy adults, allowing once-daily dosing. In renal impairment (CrCl <30 mL/min), half-life may increase to 20-30 hours requiring dose adjustment.
Dexbrompheniramine: 12-15h (prolonged in renal impairment). Pseudoephedrine: 5-8h (alkaline urine slows elimination, half-life up to 20h).
Renal excretion accounts for approximately 70% of the administered dose, primarily as unchanged drug via tubular secretion. Fecal elimination is about 10% with the remainder metabolized.
Drixoral contains dexbrompheniramine (renal: 30-50% unchanged, rest metabolites) and pseudoephedrine (renal: 70-90% unchanged, pH-dependent).
Category C
Category C
Antihistamine
Antihistamine/Decongestant